Taking out the JNK: A window of opportunity to improve cancer therapy

Petranel T. Ferrao

Research output: Contribution to journalComment/debatepeer-review

4 Citations (Scopus)


c-JUN-N-terminal kinase (JNK) signaling is a stress-induced response that enables survival of normal cells and is also utilized by cancer cells to evade therapy. Combining JNK inhibitors with standard therapies provides a potential strategy for overcoming drug resistance. Use of the optimal combination dosing and scheduling may substantially improve outcomes for cancer patients.

Original languageEnglish
Article numbere1128515
JournalMolecular and Cellular Oncology
Issue number3
Publication statusPublished or Issued - 3 May 2016
Externally publishedYes


  • Combination therapies
  • EMT
  • JNK signaling
  • dosing
  • drug resistance
  • early adaptation
  • phenotype-switching
  • scheduling
  • stress response

ASJC Scopus subject areas

  • Molecular Medicine
  • Cancer Research

Cite this